Source: Business Wire

Press Release: Verastem : Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Brian Stuglik's photo - CEO of Verastem

CEO

Brian Stuglik

CEO Approval Rating

66/100

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Read more